Key facts
- This page summarizes Adam Koppel's Form 4 filing for Solid Biosciences Inc. (SLDB).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 12 Jan 2024, 16:56.
Adam Koppel - 11 Jan 2024 Form 4 Insider Report for Solid Biosciences Inc. (SLDB)
- Reporting relationship
- Director, 10%+ Owner
- Issuer ticker
- SLDB
- Reported as of
- 11 Jan 2024
- Net transaction value
- +$5,000,005
- SEC form
- 4
- Accepted by SEC
- 12 Jan 2024, 16:56:49 UTC
- Prior SEC filing
- 18 Oct 2023
- Next SEC filing
- 07 Jun 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Adam Koppel
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Adam Koppel filed Form 4 for Solid Biosciences Inc. (SLDB) on 12 Jan 2024.
Change
- Previous filing in this sequence was filed on 18 Oct 2023.
- Current net transaction value: +$5,000,005.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
SLDB
transaction
Common Stock
Award
- Transaction value
- $5,000,005
- Shares
- +904,160
- Change %
- +29%
- Price
- $5.53
- Shares after
- 4,034,582
- Date
- 11 Jan 2024
- Ownership
- See footnotes
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
On January 8, 2024, BCLS II Equity Opportunities, LP ("BCLS II Equity") entered into a securities purchase agreement with the Issuer pursuant to which the Issuer agreed to issue and sell 904,160 shares of Common Stock to BCLS II Equity at a price of $5.53 per share (the "January 2024 Private Placement"). The January 2024 Private Placement closed on January 11, 2024.
Footnote F2
Represents shares of Common Stock held by BCLS SB Investco, LP ("BCLS SB"), Bain Capital Life Sciences Fund II, L.P. ("BCLS Fund II"), BCLS II Investco, LP ("BCLS II Investco"), BCLS II Equity and BCIP Life Sciences Associates, LP ("BCIPLS" and, together with BCLS SB, BCLS Fund II, BCLS II Investco and BCLS II Equity, the "Bain Capital Life Sciences Entities"). Bain Capital Life Sciences Investors, LLC ("BCLSI") (i) is the ultimate general partner of each of BCLS SB, BCLS Fund II, BCLS II Investco and BCLS II Equity and (ii) governs the investment strategy and decision-making process with respect to investments held by BCIPLS. Dr. Koppel is a Partner of BCLSI. As a result, Dr. Koppel may be deemed to share voting and dispositive power with respect to the securities held by the Bain Capital Life Sciences Entities. Dr. Koppel disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein.